Speciality Medicines Ltd
Incorporated in 2021, Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals.[1]
- Market Cap ₹ 250 Cr.
- Current Price ₹ 284
- High / Low ₹ 381 / 121
- Stock P/E 147
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE SME IPO
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | |
|---|---|
| 23.18 | |
| 19.60 | |
| Operating Profit | 3.58 |
| OPM % | 15.44% |
| 0.02 | |
| Interest | 0.35 |
| Depreciation | 0.30 |
| Profit before tax | 2.95 |
| Tax % | 42.71% |
| 1.70 | |
| EPS in Rs | 4.45 |
| Dividend Payout % | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | |
|---|---|
| Equity Capital | |
| Reserves | |
| Total Liabilities | |
| CWIP | |
| Investments | |
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | |
|---|---|
| -3.65 | |
| -0.12 | |
| 3.88 | |
| Net Cash Flow | 0.10 |
| Free Cash Flow | -3.73 |
| CFO/OP | -102% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | |
|---|---|
| Debtor Days | |
| Inventory Days | |
| Days Payable | |
| Cash Conversion Cycle | |
| Working Capital Days | |
| ROCE % |
Documents
Announcements
-
Intimation Of Contact Details Of Key Managerial Personnel Pursuant To Regulation 30(5) Of SEBI (LODR) Regulations 2015
28 Apr - Company disclosed KMP contact details for Regulation 30(5) and uploaded them on website.
-
Announcement under Regulation 30 (LODR)-Change in Management
28 Apr - Board met on 28 April 2026, appointed secretarial and internal auditors, and authorised KMP for disclosures.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On April 28 2026
28 Apr - Board appointed secretarial and internal auditors; authorised KMP and reviewed related party transactions.
-
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
23 Apr - Speciality Medicines signed a USD 2 million distribution deal with an international entity.
-
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
22 Apr - Company finalizes USD 1.5 million distribution deal with an international entity.
Business Profile[1]
Co. is engaged in the marketing and distribution of specialty pharmaceutical formulations, with a focus on high-cost oral and injectable drugs across key therapeutic areas including oncology, immunology, neurology, and rare diseases.